Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | CNR2 | P34972 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081742 | 0.84 | ALDH1A1 (0.73) | ALDH1A1KDM4ESMN1; SMN2MAPTHTT | |
| SCHEMBL2080681 | 0.84 | TP53 (0.65) | ALDH1A1SMN1; SMN2MAPTTP53CNR2 | |
| SCHEMBL15872007 | 0.83 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2MAPTHTTTP53 | |
| SCHEMBL4556004 | 0.83 | PKM (0.71) | ALDH1A1KDM4EMAPTHTTTP53 | |
| SCHEMBL4555634 | 0.83 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2MAPTHTTTP53 | |
| SCHEMBL8512706 | 0.81 | TNF (0.54) | ALDH1A1KDM4ESMN1; SMN2MAPTHTT | |
| SCHEMBL23326420 | 0.81 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HTTTP53MAPK1 | |
| SCHEMBL24124809 | 0.81 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HTTTP53MAPK1 | |
| SCHEMBL15052643 | 0.81 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HTTTP53MAPK1 | |
| SCHEMBL29451365 | 0.81 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HTTTP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | disclosed |
| CN-1950375-A | Glucocorticoid receptor modulator compounds and methods- utility | LIGAND PHARM INC (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1718653-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | Ligand Pharmaceuticals Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082909-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | NR3C1, NR3C2, MC2R | ALDH1A1 1465/4885KDM4E 2959/4885SMN1; SMN2 4602/4885 |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | NR3C1, NR3C2, MC2R | ALDH1A1 1465/4885KDM4E 2959/4885SMN1; SMN2 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.